FRESEN.MED.CARE KGAA O.N.
FRESEN.MED.CARE KGAA O.N./ DE0005785802 /
FME
|
2024-12-23 9:15:57 PM
|
Chg.
-0.230
|
Volume |
Bid9:59:42 PM |
Ask9:59:42 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
43.690EUR
|
-0.52%
|
31,859
Turnover: 1.4 mill. |
43.510Bid Size: 350 |
43.750Ask Size: 350 |
12.76 bill.EUR |
2.74% |
25.58 |
Business description
Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure. Around 2.8 M patients with this disease worldwide regularly undergo dialysis treatment. Dialysis is a vital blood cleansing procedure that substitutes the function of the kidney in case of kidney failure.
Management board & Supervisory board
| CEO |
| Helen Giza |
| Management board |
| Martin Fischer, Dr. Katarzyna Mazur-Hofsäß, Frank Maddux, MD, Craig Cordola |
| Supervisory board |
| Michael Sen, Stefanie Balling, Sara Hennicken, Shervin J. Korangy, Dr. Marcus Kuhnert, Gregory Sorensen, M.D., Pascale Witz, Ralf Erkens, Beate Haßdenteufel, Regina Karsch, Frank Michael Prescher, Dr. Manuela Stauss-Grabo |
Company data
| Name: |
Fresenius Medical Care AG & Co. KGaA |
| Address: |
Else-Kröner-Straße 1,D-61352 Bad Homburg |
| Phone: |
+49-6172-609-0 |
| Fax: |
+49-6172-609-2301 |
| E-mail: |
-
|
| Internet: |
www.fmc-ag.de |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
12-31 |
| Free Float: |
44.95% |
| IPO date: |
1996-10-02 |
Investor relations
| Name: |
Dr. Dominic Heger |
| IR phone: |
+49 (0) 6172 609-2525 |
| IR Fax: |
+49 (0) 6172 609-2301 |
| IR e-mail: |
ir@fmc-ag.com
|
Company calendar
|
CW 9 | 2025-02-25
Annual Report
|
|
CW 19 | 2025-05-09
Interim Report 1st Quarter/3 Months
|
|
CW 21 | 2025-05-22
General Shareholder Meeting
|
|
CW 32 | 2025-08-08
Interim Report 2nd Quarter/6 Months
|
